<DOC>
	<DOCNO>NCT01732380</DOCNO>
	<brief_summary>The aim study compare raltitrexed/oxaliplatin plus radiotherapy versus radiotherapy subject inoperable esophageal cancer .</brief_summary>
	<brief_title>A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer</brief_title>
	<detailed_description>108 patient randomized receive Raltitrexed/Oxaliplatin Plus Radiotherapy ( Raltitrexed 2.5mg/㎡ d1 , Oxaliplatin 100mg/㎡ d1 , q21d Plus Radiotherapy 2.0Gy/day , 5 times/week,6 week . ) Radiotherapy ( Radiotherapy 2.0Gy/day , 5 times/week,6 week ) subject Inoperable esophageal cancer . All patient receive therapy six week unless disease progression unacceptable toxicity . Patients evaluate every 3 month .Progression-Free-Survival primary endpoint . Response Rate , Overall survival , toxicity therapy second endpoint .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>Confirmed diagnosis inoperable esophageal cancer ( squamous cell carcinoma ) Measurable disease accord RECIST criterion Age &gt; 18 year WHO performance score &lt; 2 Estimated life expectancy &gt; 12 week Subjects consider appropriate receive systemic chemotherapy pelvic radiotherapy Hematologic function : WBC ≥ 4.0×109/L , PLT ≥ 80×109/L , Hb ≥ 10mg/dL Renal function : Cr ≤ 1.25×UNL Hepatic function : BIL ≤ 1.5×UNL , ALT/AST ≤ 2.5×UNL Documented inform consent participate trial Subjects distant metastasis Pregnancy breast feeding . Women childbearing age must use effective contraception Serious cardiovascular disease ( congestive heart failure , uncontrollable arrhythmia , unstable angina , myocardial infarction , serious heart valve disease , resistant hypertension ) Evidence bleed diathesis serious infection pregnant lactate woman Patient participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>